Latest Breaking News On - Oppenheimer holdings inc - Page 7 : comparemela.com

Aptiv (NYSE:APTV) Price Target Cut to $145 00 by Analysts at Oppenheimer

Aptiv (NYSE:APTV – Free Report) had its target price decreased by Oppenheimer from $148.00 to $145.00 in a research note published on Friday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the auto parts company’s stock. A number of other equities analysts have also recently issued reports on APTV. UBS Group upped their […]

United statesAsia pacificBenjamin lyonStratos wealth partnersRoyal bankMn services vermogensbeheerSecurities exchange commissionRaymond james associatesWells fargo companyJb capitalYork mellon corpPower solutionsFree reportModerate buyGet free reportExchange commission

AGCO (NYSE:AGCO) PT Lowered to $145 00

AGCO (NYSE:AGCO – Free Report) had its price target decreased by Oppenheimer from $154.00 to $145.00 in a research report released on Friday, Benzinga reports. Oppenheimer currently has an outperform rating on the industrial products company’s stock. Several other analysts also recently commented on the stock. StockNews.com downgraded shares of AGCO from a buy rating […]

Jpmorgan chase coCompany profileGroup ltdManchester capital managementFree reportModerate buyGet free reportCapital managementNyse agcoIndustrial productLower price targetOppenheimer holdings inc

Oppenheimer Reiterates Market Perform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Oppenheimer reiterated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $19.00 target price on the biopharmaceutical company’s stock. ACAD has been the topic of a number of other research reports. JPMorgan Chase & Co. decreased their price […]

United statesRobertw bairdBrendan teehanStephen davisQuest partnersPharmaceuticals dailyPharmaceuticals trading downRoyal bankSecurities exchange commissionLegato capital managementChina universal asset management coPharmaceuticals incJpmorgan chase coAcadian asset managementPharmaceuticals company profileFree report

ACADIA Pharmaceuticals (ACAD) Market Perform Rating Reaffirmed at Oppenheimer

Oppenheimer restated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $19.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on ACAD. Mizuho cut shares of ACADIA Pharmaceuticals from […]

United statesZurcher kantonalbank zurich cantonalbankJames kiharaStephen davisMirae asset global investments coMorgan stanleyPharmaceuticals stock downPharmaceuticals incPharmaceuticals company profileEmerald mutual fund advisersRaymond james associatesPharmaceuticals dailyEmerald advisersRoyal bankFree reportModerate buy

Investment Analysts Updated EPS Estimates for May 7th (AAWH, AGEN, CART, CLSK, CMPR, CRNT, DAWN, DDOG, DIS, ESPR)

Investment Analysts Updated EPS Estimates for May 7th (AAWH, AGEN, CART, CLSK, CMPR, CRNT, DAWN, DDOG, DIS, ESPR)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Needham companyAscend wellness holdings incGh researchBarrington researchOppenheimer holdings incNational cinemediaCeragon networksInvestment analystOne biopharmaceuticalsAscend wellness holdings inc daily